Catridecacog

Catridecacog is a prescription medication used to prevent bleeding in people with a rare blood clotting disorder known as congenital Factor XIII A-subunit deficiency. This medication replaces an important protein necessary for normal clotting.

Catridecacog comes in an injectable form to be given directly into a vein (IV) by a healthcare professional. In some cases, patients can be taught to properly administer this medication.

Common side effects include headache and pain at the site of injection. 

Catridecacog is a prescription medication used to prevent bleeding in patients with congenital factor XIII A-subunit deficiency.

Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.

The dose your doctor recommends may be based on the following your weight.

The recommended dose/dose range of catridecacog (Tretten) is 35 IU/kg dose.

Serious side effects can occur including:

• hypersensitivity reactions. This medication is a recombinant protein and it may cause allergic reactions including anaphylactic reaction (a severe allergic response). Tell your healthcare provider if you have signs of an allergic reaction including hives, rash, tightness of the chest, wheezing, low blood pressure and anaphylaxis.
• thrombosis (blood clot formation). Increased levels of activated rFXIII may increase the risk of thrombosis. In case of predisposition to conditions of thrombosis, caution should be exercised due to the fibrin-stabilizing effect of this medication.

In clinical trials, the most frequent adverse drug reactions were non-neutralizing antibodies. The antibodies had no inhibitory effect and the patients did not experience any adverse events or bleeding in association with these antibodies.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take factor VIIa.

This is not a complete list of catridecacog drug interactions. Ask your doctor or pharmacist for more information.

Tell your healthcare provider if you are pregnant or planning to become pregnant. It is not known if this medication will harm your unborn baby. Catridecacog should be used only if the benefits clearly outweigh the risks.

Tell your healthcare provider if you are breastfeeding. It is not known if this medication is excreted in human breast milk or if it will harm your nursing baby. The decision to continue or discontinue breastfeeding or catridecacog therapy should be based on benefits to child and mother.

Tell your doctor if you notice any breakthrough bleeding.

Catridecacog is given as an injection into your vein (intravenous injection). These injections are given once a month.

In some cases, patients can be taught to properly administer this medication. Do not attempt to do an infusion yourself unless you have been taught by your healthcare provider.